Lisle Jennifer W, Eary Janet F, O'Sullivan Janet, Conrad Ernest U
Department of Orthopedics and Sports Medicine, University of Washington, Seattle, WA, USA.
Clin Orthop Relat Res. 2009 Jun;467(6):1605-11. doi: 10.1007/s11999-008-0647-z. Epub 2008 Dec 2.
Synovial sarcoma generally is associated with poor prognosis. With recent advances in molecular biology, it has become apparent not all synovial sarcomas share the same tumor biology. (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for risk assessment in several types of sarcomas. We therefore assessed the clinical value of (18)F-FDG-PET-derived maximum standard uptake value (SUV(max)) for predicting survival in patients with synovial sarcoma. (18)F-FDG-PET was performed in 44 patients with synovial sarcoma before therapy and resection. SUV(max) was calculated for each tumor and then evaluated for prognostic usefulness along with metastasis at presentation, tumor grade, histopathologic subtype, age, gender, postsurgical margins, anatomic location, and tumor size for overall survival and progression-free survival. SUV(max) ranged from 1.2 to 13.0 (median, 4.35). Pretherapy tumor SUV(max) predicted overall survival and progression-free survival. Patients presenting with a SUV(max) greater than 4.35 had a decreased disease-free survival and were therefore at high risk for having local recurrences and metastatic disease.
Level I, diagnostic study. See the Guidelines for Authors for a complete description of levels of evidence.
滑膜肉瘤通常预后较差。随着分子生物学的最新进展，已明显发现并非所有滑膜肉瘤都具有相同的肿瘤生物学特性。（18）F-氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）对几种类型的肉瘤的风险评估有用。因此，我们评估了（18）F-FDG-PET衍生的最大标准摄取值（SUV（max））对预测滑膜肉瘤患者生存的临床价值。对44例滑膜肉瘤患者在治疗和切除前进行了（18）F-FDG-PET检查。计算每个肿瘤的SUV（max），然后结合就诊时的转移情况、肿瘤分级、组织病理学亚型、年龄、性别、手术切缘情况、解剖位置和肿瘤大小，评估其对总生存和无进展生存的预后价值。SUV（max）范围为1.2至13.0（中位数为4.35）。治疗前肿瘤SUV（max）可预测总生存和无进展生存。SUV（max）大于4.35的患者无病生存期缩短，因此发生局部复发和转移性疾病的风险较高。
I级，诊断性研究。有关证据水平的完整描述，请参阅作者指南。
